AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

AnaptysBio plans to spin off its biopharma operations into a new company, First Tracks Bio, in ~1-2 months, while the legacy AnaptysBio will remain a royalty-focused vehicle. The royalty company retains two partnered programs: Jemperli (dostarlimab) with GSK and imsidolimab with a PDUFA date at year-end being sold by Vanda. The biopharma spinout houses pipeline assets including AMB033 (CD122 antagonist) in celiac disease and EoE (Phase Ib) and rosnilimab (PD-1 depleter) which showed positive Phase IIb arthritis data; management will meet the FDA this quarter to discuss Phase III and is seeking strategic/financial capital.

Analysis

The corporate reorganization creates two distinct risk/return profiles: one asset with predictable, royalty-like cashflows and another that concentrates early-stage clinical and financing risk. Market participants price those profiles very differently — royalty streams trade on duration and yield (sensitive to discount rates and PDUFA-like binary outcomes elsewhere), while the development entity trades on binary clinical and financing milestones that can swing >2x on a single readout or partnership announcement.

Second-order effects favor firms and specialists in biopharma financing and BD: royalty investors, structured-credit buyers, and large pharmas with balance-sheet optionality. Conversely, pure-play small-cap immunology peers that must raise equity to fund Phase III work will face wider discount windows, pushing them to accept less-favorable partner terms or dilutive financings, which could compress their market caps by 30-50% in stressed windows.

Operational and supply-chain friction is under-appreciated: demand for CMC slots, viral- or cell-based fill/finish capacity, and ADCC/effector-optimized antibody manufacturing could tighten as multiple depleting/effector platforms race to pivotal studies. That increases the economic value of early manufacturing contracts but also raises execution risk (delays, CMC comparability questions) that can shift timelines by quarters.

Key catalyst cadence to watch spans near-term corporate/BD announcements and medium-term regulatory/partnering outcomes; both can re-rate each investment bucket asymmetrically. Tail risks include an adverse safety signal for depleting modalities that would impair investor appetite across the therapeutic class, and a poorly executed separation that forces the development arm to take dilutive bridge financing at suboptimal terms within 6–12 months.

Key Decisions for Investors

• ANAB (equity) — Buy into the post-reorg clarity window: initiate a 6–12 month long position size 2–3% of NAV. Thesis: royalty-like cashflows should re-rate versus early-stage optionality; target +30–50% if market reprices on confirmed non-dilutive cashflows. Risk: 30–40% downside if commercialization royalties underperform or market-wide risk-off hits small-cap biotechs. Use a 30% stop or hedge with a 3–6 month put to limit tail risk.
• ANAB (options/collar) — If liquid options exist, construct a funded 9–15 month bullish collar (long LEAP call or buy equity + sell higher-call / buy lower-strike put) to capture upside from corporate re-rating while capping downside to ~15–20%. Cost-effective way to capture >2x upside on successful partnership/PDUFA-like outcomes while limiting capital at risk to ~5% of position notional.
• Pair trade (event-driven) — Long ANAB royalty exposure (2% NAV) / Short a high-burn small-cap immunology name (size matched by notional exposure) for 3–9 months. Rationale: divergence between de-risked cashflows and high-burn development companies should widen if capital markets tighten. Reward: capture relative spread compression; Risk: class-wide rally or a takeover of the short could produce losses — cap exposure and use tight stop-losses.
• GSK (selective, small position) — Buy a tactical, modest long (0.5–1% NAV) with a 6–18 month horizon as a hedge against potential M&A activity for attractive mid-stage immunology assets. Upside is takeover optionality or strategic bolt-on benefits; downside is limited versus large-cap cyclicality. Keep position size small: this is convex optionality, not a primary thesis.